Kalaris Therapeutics, Inc. (KLRS)Healthcare | Biotechnology | Berkeley Heights, United States | NasdaqGM
4.42 USD
-0.02
(-0.450%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 4.50 +0.08 (1.810%) ⇧ (July 13, 2026, 4:32 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 3:22 a.m. EDT
The immediate outlook remains heavily skewed toward caution due to a brutal multi-year price collapse. Despite a recent 7.8% pop and insider buying, the stock has lost 99.44% of its value over the last four years, with every single year showing a double-digit decline. This relentless downward trajectory suggests the market has thoroughly priced out the current business model, rendering any short-term technical bounce a potential trap rather than a genuine reversal. The fundamental picture is dire: negative earnings, massive cash burn, and no dividend support. While the insider purchase and upcoming reverse merger offer a narrative of potential transformation, the lack of a proven track record and the sheer depth of the prior decline mean there is no safe entry point for a standard investment thesis. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.080181 |
| AutoTheta | 0.093431 |
| MSTL | 0.182514 |
| AutoETS | 0.185452 |
| MSTL_105 | 0.243686 |
Forecast horizon: 60 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 34% |
| H-stat | 1.49 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.373 |
| Excess Kurtosis | -0.33 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.057 |
| Market Cap | 105,161,872 |
| Forward P/E | -2.72 |
| Website | https://kalaristx.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.70114946 |
| Address1 | 400 Connell Drive |
| Address2 | Suite 5500 Berkeley Heights |
| All Time High | 1,126.08 |
| All Time Low | 2.14 |
| Ask | 5.45 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 66,460 |
| Average Daily Volume3 Month | 84,852 |
| Average Volume | 84,852 |
| Average Volume10Days | 66,460 |
| Bid | 3.22 |
| Bid Size | 2 |
| Book Value | 2.982 |
| City | Berkeley Heights |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.42 |
| Current Ratio | 12.188 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 4.5 |
| Day Low | 4.24 |
| Debt To Equity | 2.057 |
| Display Name | Kalaris Therapeutics |
| Earnings Timestamp End | 1,754,569,800 |
| Earnings Timestamp Start | 1,754,569,800 |
| Ebitda Margins | 0.0 |
| Enterprise Value | 9,356,869 |
| Eps Current Year | -2.02625 |
| Eps Forward | -1.62625 |
| Eps Trailing Twelve Months | -0.78 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.745 |
| Fifty Day Average Change | -0.3249998 |
| Fifty Day Average Change Percent | -0.06849311 |
| Fifty Two Week Change Percent | 70.114944 |
| Fifty Two Week High | 11.88 |
| Fifty Two Week High Change | -7.46 |
| Fifty Two Week High Change Percent | -0.62794614 |
| Fifty Two Week Low | 2.14 |
| Fifty Two Week Low Change | 2.28 |
| Fifty Two Week Low Change Percent | 1.0654205 |
| Fifty Two Week Range | 2.14 - 11.88 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,596,115,800,000 |
| Float Shares | 7,219,053 |
| Forward Eps | -1.62625 |
| Forward P E | -2.7179093 |
| Free Cashflow | -27,217,376 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 20 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.08811 |
| Held Percent Institutions | 0.77876 |
| Implied Shares Outstanding | 23,792,278 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,736,985,600 |
| Last Split Factor | 1:23 |
| Long Business Summary | Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey. |
| Long Name | Kalaris Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 105,161,872 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_1900954228 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -44,098,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 105,637,714 |
| Number Of Analyst Opinions | 7 |
| Open | 4.405 |
| Operating Cashflow | -42,510,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 650 249 2727 |
| Post Market Change | 0.07999992 |
| Post Market Change Percent | 1.809953 |
| Post Market Price | 4.5 |
| Post Market Time | 1,783,974,733 |
| Previous Close | 4.44 |
| Price Eps Current Year | -2.1813698 |
| Price Hint | 4 |
| Price To Book | 1.4822266 |
| Profit Margins | 0.0 |
| Quick Ratio | 12.033 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.02 |
| Regular Market Change Percent | -0.45045 |
| Regular Market Day High | 4.5 |
| Regular Market Day Low | 4.24 |
| Regular Market Day Range | 4.24 - 4.5 |
| Regular Market Open | 4.405 |
| Regular Market Previous Close | 4.44 |
| Regular Market Price | 4.42 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 68,011 |
| Return On Assets | -0.27966 |
| Return On Equity | -0.66598 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 23,792,278 |
| Shares Percent Shares Out | 0.0211 |
| Shares Short | 502,578 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 801,523 |
| Short Name | Kalaris Therapeutics, Inc. |
| Short Percent Of Float | 0.060399998 |
| Short Ratio | 6.12 |
| Source Interval | 15 |
| State | NJ |
| Symbol | KLRS |
| Target High Price | 25.0 |
| Target Low Price | 7.0 |
| Target Mean Price | 18.71429 |
| Target Median Price | 20.0 |
| Total Cash | 97,215,000 |
| Total Cash Per Share | 4.086 |
| Total Debt | 1,410,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.78 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.6839 |
| Two Hundred Day Average Change | -2.2638998 |
| Two Hundred Day Average Change Percent | -0.3387094 |
| Type Disp | Equity |
| Volume | 68,011 |
| Website | https://kalaristx.com |
| Zip | 7,922 |